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                                    List of abbreviations 
ACTH    adrenocorticotropic hormone 
ADA      American Diabetes Association 
BGGI     borderline gestational glucose intolerance  
BMI       body mass index 
CGR      C-peptide-to-glucose ratio 
FCGR    fasting C-peptide-to-glucose ratio 
2CGR    2-hour C-peptide-to-glucose ratio   
GCT       glucose challenge test 
GDM      gestational diabetes mellitus 
GH         gestational hypertension  
HCG       human chorionic gonadotrophin 
HPL        human placental lactogen  
IR           insulin resistance  
NRDS    neonatal respiratory distress syndrome 
NGT      normal glucose tolerance  
OGTT    oral glucose tolerance test 
PE          pre-eclampsia 
PRL        prolactin 
SD         standard deviation  
SP 1       Schwangerschafts-protein 1, beta-1- glikoprotein 
TNF       tumor necrosis factor 
WHO     World Health Organization 
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1. Introduction, literature overwiev 
 
 
     Gestational diabetes mellitus (GDM) is defined as any degree of glucose intolerance with 
first recognition during pregnancy. The definition applies irrespective of whether insulin or 
dietary only treatment is utilized and whether the condition persists after pregnancy. It does 
not exclude the possibility that unrecognized glucose intolerance may have antedated or 
begun concomitantly with the pregnancy. Most often this abnormal glucose tolerance returns 
to normal postpartum. Reclassification of maternal glycemic status should be performed at 
least 6 weeks after delivery. The prevalence of GDM ranges from 1 to 14 % of all 
pregnancies, however it depends on the diagnostic criteria used and the ethnic background of 
the population being tested. Earlier reports from Hungary reported that the frequency of GDM 
was between 1-3%. More recent reports from our country however detected higher 
frequencies up to 7.7%. The term GDM was introduced by O’ Sullivan in 1961. The glucose 
intolerance of GDM is usually mild but perinatal mortality associated with this complication 
is 4 to 5 times increased compared to the general pregnant population. Macrosomia, 
intrauterine growth retriction, neonatal cardiomymiopathia, hypoglycaemia, jaundice, 
polycythemia, neonatal respiratory distress syndrome (NRDS) and hypocalcaemia may also 
effect newborns of GDM mothers. Offsprings of women with GDM are at increased risk of 
obesity, glucose intolerance, and diabetes in late adolescence and young adulthood. GDM is 
associated with an increased frequency of maternal hypertensive disorders and need for 
caesarean delivery. Moreover, GDM also considerably increases the woman’s risk of 
developing manifest diabetes later in life. Thus, it is important to recognize and treat this 
disease. Obesity and other factors that promote insulin resistance appear to enhance the risk of 
type 2 diabetes after GDM, while markers of islet cell-directed autoimmunity are associated 
with an increase in the risk of type 1 diabetes.  
    The mechanisms involved in the development of this temporary diabetic state are still 
partly unknown. Among the possible explanations are reduced insulin secretion, increased 
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insulin degradation, increased secretion of hormones with anti-insulin effect (human placental 
lactogen [HPL], human chorionic gonadotrophin [HCG] prolactin [PRL] Schwangerschafts-
protein 1, beta-1- glikoprotein [SP 1], estrogen, progesterone, cortisol and adrenocorticotropic 
hormone [ACTH]), reduced tissue sensitivity to insulin, or a combination of two or more 
these mechanisms. As glucose tolerance in pregnancy decreases in parallel with increasing 
levels of pregnancy-related hormones and of cortisol (until 37 week of gestation), it has been 
suggested that one or more of these hormones might be implicated in bringing about 
alterations in carbohydrate metabolism. Recently, the role of tumor necrosis factor (TNF) alfa 
and leptin has been suggested as they have numerous effects on carbohydrate metabolism. 
Pregnancy is a state of insulin resistance. In late pregnancy fasting serum insulin 
concentration is almost doubled compared to postpartum levels, both in normal pregnant and 
in gestational diabetic women. However, the insulin response to oral glucose or a mixed meal 
is significantly greater in normal pregnant women than in the gestational diabetic subjects. 
GDM women compared to normal pregnant controls have relative insulin-deficiency. An 
increased insulin demand of normal pregnancy is assured by the increase in the number and 
the size of islets of Langerhans.  
     If insulin production in unable to compensate for the insulin resistance (IR) of pregnancy, 
GDM will develop. Most GDM cases develop between the 24 and 28 weeks of gestation. This 
is the period hen in the absence other risk factors screening of GDM should be performed in 
all pregnant patients by a 75-gram OGTT (oral glucose tolerance test). Undiagnosed and 
untreated patients with GDM as well as their fetuses are at a higher risk of pregestional 
diabetes. Obstetric and perinatal outcomes in newborns of gestational diabetic women are 
related to metabolic control and fetal surveillance during pregnancy. If gestational diabetic 
subjects receive optimal care during gestation, the risk of maternal complications and 
perinatal morbidity is similar to those observed in normal pregnancies. 
   Since GDM has no signs or symptoms, it can only be recognized by screening. GDM is 
screened by a number of different methods. Screening for GDM is universally recommended 
despite the lack of consensus about the optimal screening method. The American Diabetes 
Association (ADA) recommends a two-step approach: All pregnant women should be 
screened for GDM between 24 to 28 weeks of gestation using a 50-gram 1-hour oral glucose 
challenge test (GCT) with a threshold for further testing of 140 mg/dl (7.8 mmol/l) or higher. 
The diagnosis of GDM is based on the 100-gram OGTT. Two or more of the venous plasma 
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glucose concentrations must be met or exceeded the values below for the diagnosis: fasting: 
5.3 mmol/l, 1-h: 10.0 mmol/l, 2-h: 8.6 mmol/l, 3-h: 7.8 mml/l.  
There is a controversy regarding the screening method for GDM. There are rational 
arguments both for a universal screening and for a selective screening within high risk groups. 
Selective screening for GDM is recommended according to the ADA. Low-risk pregnant 
women need no glucose testing by the ADA: Age < 25 years; weight normal before 
pregnancy; member of an ethnic group with a low prevalence of GDM; no know diabetes in 
first-degree relatives; no history of abnormal glucose tolerance; no history of poor obstetrics 
outcome. Using this criteria screening for GDM is not required in 10-36% of pregnant 
women, but up to 3% GDM remains undetected. For this reason all gravid women need to be 
screened for GDM. Risk screening for GDM: risk assessment should be undertaken at the first 
prenatal visit. Markers of high risk for GDM are shown in Table 1. 
 
Table 1. Markers of high risk for GDM: 
- Age (>35 years) 
- obesity (BMI ≥ 30 kg/m2) 
- marked family history of diabetes or glycosuria 
- personal history of GDM: 
                                             -  stillbirth 
                                             -  birth defect       
                                             -  macrosomia 
                                             -  weight gain 
                                             -  polyhydramnion 
                                             -  hypertension 
 
Women with clinical characteristics consistent with a high risk of GDM should undergo 
glucose testing as soon as feasible. If they are found not to have GDM at that initial screening, 
they should be retested between 24 to 28 weeks of gestation. 
          Until 1995 the screening of GDM only included women with glucosuria or with a 
positive family history of diabetes in our hospital. At that time the incidence of GDM was 
only 1.11%. Between 1995 and 1997 general screening for GDM was initiated with a 40-gram 
standard breakfast test meal (1 roll of bread and 2 decilitres of milk). At that time the 
incidence of GDM increased to 2.07%. Since the incidence of GDM was much lower than the 
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valid figure for the rest of the country, general screening with the 75-gram OGTT was 
initiated in all pregnancies between 24 and 28 weeks of gestation was started in Szekszárd in 
1997. GDM was diagnosed if the fasting value was at or above 7.0 mmol/l, or 2-h post 
challenge value was at or above 7.8 mmol/l (World Health Organization /WHO/).  
       Parallel with the increasing levels of placental hormones till 37 weeks of pregnancy, the 
diabetic impact of pregnancy also increases. Consequently if glucose levels are around the 
upper limit of the normal range between 24 and 28 weeks of gestation these might further 
increase and cross the cut-off values in subsequent weeks. Due to the above if the OGTT 
result are normal, but the fasting glucose was between 6.0 and 7.0 mmol/l and/or a postload 
glucose between 6.8 and 7.8 mmol/l (glucose levels around the upper limit of the normal 
range) repeat testing was recommended within a month. After a pilot done on 136 women 
who were invited to a repeated screening 67 actually participated (49.3%) and GDM was 
diagnosed in 20 of the 67 (29.9) in 1999. The incidence of GDM increased from 3.9% 
without the repeat screening to 5.1%. In the light of these results we routinely recommended 
the repeat screening to women with these borderline values in the whole of Tolna County .  
  Hypertensive disorders in pregnancy are major causes of maternal, fetal and neonatal 
morbidity and mortality. They are associated with an elevated risk of seizures, stroke, 
hepatic and renal failure, coagulation disturbances, placental abruption, intrauterine growth 
restriction, fetal distress, premature delivery, and death. Approximately 6 to 9 % of 
pregnancies are complicated by gestational hypertension (GH), while pre-eclampsia (PE) 
occurs in 3 to 4% of pregnancies, usually in the second or third trimesters. It may also 
present up to six weeks post-partum. 
       The pathophysiology of hypertensive disorders in pregnancy is poorly understood but it is 
likely to be multifactorial. Several studies suggest that glucose intolerance and insulin 
resistance (IR) may play a role in the aetiology of these diseases, as the incidence of 
hypertensive disorders is twice as high in pregnancies of glucose intolerant women compared 
to women with normal glucose tolerance (NGT). The levels of C-peptide in the blood are 
measured instead of insulin levels and used as an indicator of IR. Insulin is initially 
synthesized in the form of proinsulin.  In this form the A-and B-chains of active insulin are 
linked by a third polypeptide chain called the connecting peptide, or C-peptide, for short 
/Figure 1/. Equimolar amounts of C-peptide and insulin release from pancreatic beta cells to 
the portal circulation. IR and related hyperinsulinemia are associated with essential 
hypertension in non-pregnant individuals. In addition to the direct role in glucose metabolism, 
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insulin may additionally modify other physiological pathways that are indirectly or directly 
involved in sodium and water balance, and vascular resistance.  
 
Figure 1. Human proinsulin 
 
 
 
The prevalence of elevated blood pressure is doubled among overweight patients compared to 
normal-weight subjects. Furthermore, the observations of Pollare et al. suggest that the 
association between hypertension and IR is independent of obesity: relative IR was found not 
only in obese but also in lean hypertensive subjects compared to normotensive ones. 
Physiological changes during pregnancy lead to a decrease in insulin-sensitivity. As gestation 
advances, a progressive increase in insulin production to glucose can be found in the maternal 
pancreas. It has been shown that obesity plays a role in the development of IR in pregnancy. 
Patients with GDM are more insulin-resistant compared to control pregnant subjects with 
normal glucose tolerance. GH has been associated with hyperinsulinemia. No similar 
associations were reported regarding the relationship between PE and IR either in 
normoglycemic pregnancies or in GDM. PE is associated with a failure of trophoblast 
invasion to the spiral arteries of the placenta and it may lead to impaired uteroplacental 
perfusion and to the release of several vasoactive factors into the maternal circulation that 
finally causes endothelial dysfunction, vasoconstriction, and hypertension.   
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                                   2.  Aims 
 
 
 
      Based on the issues detailed in the introduction, our aims of were the following. The goal 
of first part of this study was to examine the incidence of gestational pathology in Tolna 
County, where 240 thousand people live and to show that the repeated screening for GDM is 
worthwhile. Until 2000 no data was available on the incidence of GDM in the whole county. 
The aim of this study was to determine the usefulness of a repeated screening for GDM 
during a given pregnancy in a population-based study in our country, too. The author also 
sought to clarify the role of certain risk factors (age, BMI, and number of pregnancies) in 
detail separately. 
      To our best knowledge, there are no population-based studies comparing IR values 
between women with GH and PE taking into account the potential effect of pre-pregnancy 
body mass index (BMI) on this association. In the second part of study we intended to 
investigate any possible correlation between IR and subsequent GH and PE in 
normoglycaemic and gestational diabetic pregnant women. Furthermore, we aimed to assess 
whether this correlation was independent of maternal weight. 
 
 
 
                       3. Patients and methods 
 
 
 
    The first part of the study: It is a population-based screening program. The screening test 
(75-gram OGTT) was offered to all pregnant women without previously diagnosed diabetes in 
the city of Szekszárd since 1997. The program was extended in 1999 to cover the whole of 
Tolna County. Tolna County has a population of approximately 240,000. The 75-gram OGTT 
was performed according to WHO recommendation between 24 and 28 weeks of gestation. 
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Venous blood samples were collected following an overnight fast (≥ 8 hrs) and 2 hour after 
glucose ingestion. All glucose samples were measured by a glucose oxidase kit (Diagon Ltd, 
Hungary). According to WHO criteria, GDM was diagnosed if the fasting glucose was ≥ 7.0 
mmol/l, or the 2-hour glucose ≥ 7.8 mmol/l. If the OGTT result was negative, but fasting 
glucose was between 6.0 and 7.0 mmol/l and/or a post-load glucose was between 6.8 and 7.8 
mmol/l a repeat OGTT was scheduled within a month.  
     Data on age, pre-pregnancy anthropometric measures, and parity was collected by 
questionnaires sent to the district nurses who organized the care of all pregnant women in the 
county during 2000. Pre-pregnancy body mass index was calculated as pre-pregnancy weight 
in kilograms divided by height in meters squared. 
     Gestational age was determined on the basis of the woman’s last normal menstrual period 
if it coincided within 1 week of the date determined by ultrasound done between 16 and 20 
weeks of gestation, otherwise we used the ultrasound estimates. 
     The study design was reviewed and approved by the local Ethical and Research 
Committees. 
     Data are shown as mean  standard deviation (SD) or percentages. Comparisons between 
groups were made using chi-square test for categorical and 2-sample t-tests for continuous 
variables. The threshold of statistical significance was set at p<0.05. Binomial proportions 
were used to estimate 95% confidence intervals around the observed frequencies. 
     The second part of the study: This population-based study was carried out in the Tolna 
County Balassa Janos Hospital between 1 August, 2001 and 1 March, 2007. The study design 
was reviewed and approved by the local Ethical and Research Committees, too. All women 
received written information on the aims and procedures related to the study from their 
attending obstetricians. During the study period that lasted for more than 5 years altogether 
5,962 deliveries were registered in the hospital database. Of these deliveries 317 (5.3%) were 
preterm deliveries, 65 (1.1%) twin gestations, and 1,566 (26.6%) Caesarean deliveries. Of 
these women a total of 5,671 (95.1%) had OGTT results available and registered in the Tolna 
county hospital. The main reasons for the missing OGTTs were the following: women did not 
go for GDM screening, or they did not go to prenatal care, or only fasting blood glucose was 
measured, or 40-gram carbohydrate load was utilized. 
The serum glucose levels during the diagnostic OGTTs were analyzed in 3 laboratories 
reflecting the dwelling-places of the participants. C-peptide determination (fasting and 2 h) 
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was however performed only in one of these laboratories, thus leading to the exclusion of 
1979 pregnancies without C-peptide determination. Of the remaining 3,692 women further 
738 were excluded due to delivery in another place (n=647), preterm delivery (<36 weeks of 
gestation, n=35), twin gestations (n=38), and due to prepregnancy or early pregnancy 
hypertension (n=18) leaving 2,954 records for the current analysis. (The twin pregnancies 
were excluded as these might lead to heightened IR owing to a larger placental mass). Serum 
glucose was analysed using a glucose oxidase kit (Diagon Ltd. Hungary), C-peptide was 
determined by a competitive radioimmunoassay (Biodata, Rome, Italy; coefficient of 
variation: 1.4%/1.0 ng/ml; sensitivity: <0.01 ng/ml of the C-peptide kit). 
Blood pressure was measured after a 10-minute rest with the patient in a sitting position at 
the first obstetrical visit, and in the middle of gestation (between 18 and 22 weeks of 
gestation), then weekly after 36 weeks of gestation. Blood pressures were measured in 
duplicate, 5 minutes apart. Chronic hypertension was defined as a blood pressure of 140/90 
mm Hg or higher on two occasions before 20 weeks of gestation, or persisting beyond 12 
weeks postpartum. GH was defined as elevated systolic (≥140 mmHg) and/or diastolic (≥90 
mmHg) blood pressure on at least two occasions 6 h apart after 20 weeks of gestation. PE was 
defined as GH in association with proteinuria (≥300 mg/24-hour period), in the absence of 
urinary tract infection. 
The control group (control NGT) was composed of 2,583 normotensive subjects with 
normal OGTT results. The control group of the GDM (control GDM) was composed of 139 
normotensive pregnant women with gestational diabetes. 
GDM was diagnosed if the fasting serum glucose level was ≥7.0 mmol/l or the 2-hour 
postload serum glucose was ≥7.8 mml/l. 
The C-peptide-to-glucose ratio (CGR) was calculated as the ratio of serum C-peptide 
(milimoles per liter -ng/mlx0,331=mmol/l-) to serum glucose (mmol/l). The ratio of serum C-
peptide to serum glucose can refer to IR: higher values indicate IR, lower value indicate 
higher insulin sensitivity. 
Pre-pregnancy BMI (pre-pregnancy weight in kilograms divided by height in meters 
squared) was calculated. Pre-pregnancy anthropometrical data was drawn from the records of 
the district doctors collected at the first obstetrical visit. Maternal weight gain was defined as 
the difference between the final and initial maternal weight. The final maternal weight was 
measured in the delivery room. 
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    Lower BMI subgroup: Since the BMI values were significantly different between the 
hypertensive groups (PE NGT=25.9 kg/m
2 
GH NGT=27.4 kg/m
2
 PE GDM=28.3 kg/m
2
 GH 
GDM=31.8 kg/m
2
) and the respective control groups (GDM 23.1 kg/m
2
, without GDM 25.4 
kg/m
2
), a lower BMI subgroup was formed within the PE and GH groups with and without 
GDM. Starting with the women with the lightest weight of GH and PE groups women were 
added individually to the lower BMI (l.BMI) group until the mean BMI value of the 
respective control group was reached (non-GDM women: PE l.BMI NGT=22.9 kg/m
2
, GH 
l.BMI NGT=23.6 kg/m
2 
versus control NGT=23.1 kg/m
2
, GDM women: PE l. BMI 
GDM=25.9 kg/m
2 
GH l. BMI GDM=25.8 kg/m
2 
versus control GDM=25.4 kg/m
2
). With the 
use of these l. BMI groups, we could investigate whether the IR differences between in 
different hypertentensive and normotensive groups were confounded by higher BMI.  
Data were shown as mean  standard deviation (SD). Statistical analyses were performed 
using Chi-square tests for categorical and one-way analysis of variance (ANOVA) for 
continuous variables. Statistical significance was inferred at a two-tailed P < 0.05. 
 
 
                                   4.  Results 
 
 
 
    In the first part of the study the results were the following: 2,281 babies out of the 2,260 
deliveries were born in our county during 2000. Detailed information was collected on 
standardized questionnaires by district nurses on 2,138 (94.6%) of there pregnancies. Further 
125 pregnancies were excluded where the OGTT data was incomplete leaving a final sample 
of 2,013 for further analysis (Table 2). Of these GDM cases 167 (8.3%, 95% confidence 
interval [CI]: 7.1-9.6%) were diagnosed during the first OGTT (24-28 weeks of gestation). 
Intermediate (non-diagnostic) results were obtained in 216 women (10.7% 95%CI: 9.4-
12.2%) and thus they were invited for a further testing within a month. 
    Of the 216 invited, only 143 (66.2%) participated in the repeat examination. Among the 
143 participants 20 (14.0% 95%CI: 5.3-27.9%) GDM cases were diagnosed during the repeat 
screening. After all out of 2,013 women, 187 (9.3%) were diagnosed with GDM. If all 216 
women had gone to the repetition, then probably 30 women would have had GDM instead of 
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20. Thus the prevalence of GDM would be 9.8% instead of 9.3%.By the extrapolation of these 
binomial proportions to the 216 invited women, we would expect 30 (95%CI 11-60) more 
GDM cases to be diagnosed. 
 
Table 2. 75-gram OGTT has not been used (n=125) 
 
 
 
 
 
         Serum glucose determination did not happen                                        n      %                                       
      ________________________________________________________________________ 
 
               Women did not go to screening test for GDM                                     62   49.6 % 
 
               Patients did not go to prenatal care                                                      27   21.6 % 
 
               
________________________________________________________________________ 
 
                Fasting serum glucose has been used only                                            n      % 
      ________________________________________________________________________ 
 
 
                 Pregnant subjects vomited glucose solution                                        10    8.0 %  
 
                 Fasting blood glucose has been planned only                                        9    7.2 %         
 
                 Women refused to drink the glucose solution                                        5    4.0 % 
 
        _______________________________________________________________________           
 
                  A loading test containing 40-gram carbohydrate has been used      12    9.6 % 
      ________________________________________________________________________ 
 
     
 
The characteristics of 187 GDM women compared to 1826 controls are listed in Table 3: 
GDM women were significantly older, had a higher BMI and increased fasting and postload 
glucose during the OGTT. 
     Although a linear increasing trend of GDM risk was obvious in all 3 investigated 
parameters (age, BMI, number of pregnancies) according to the χ
2
-tests, surprisingly the 
highest point estimates were found not in the groups within the highest strata: GDM risk was 
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highest in 30-39 yrs old women (14.4%), in women with a BMI of 25-29.9 kg/m
2 
(13.5%), 
and during 3rd pregnancies (14.2%). It seems that the risk does not increase any further with 
an increasing level of the risk factor beyond the previously described groups.    
 
Table 3: Characteristics of screened women by GDM status 
 
                                                        Norm. OGTT        GDM             all mother 
                                                             n=1826             n=187              n=2013 
____________________________________________________________________ 
Age (yars)                                          26.3 5.2         28.6 5.4*         26.55.0 
Pregravid BMI (kg/m²)                       23.14.6          24.74.7*          23.44.5 
Number of pregnancies                         2.32.0            2.62.2            2.41.7 
Parity                                                     2.01.3            2.21.2            2.01.2 
Fasting blood glucose (mmol/l)            4.31.2            4.90.8*          4.41.3 
Postload blood glucose (mmol/l)          5.31.5            8.81.3*          5.41.4 
____________________________________________________________________ 
 
* p<0.01 GDM vs. normal OGTT       Mean±SD 
 
In the second part of study period, 2,954 expectant women were included in the study, 183 
(6.2%) developed GH and 49 (1.7%) PE. GDM was diagnosed in 6.0 % of the participants 
(176/2,954). The incidence of GH among GDM women was 15.9% (28/176) and of PE was 
5.1% (9/176) compared to 5.6% (155/2,778) and 1.5% (40/2778) among normoglycemic 
pregnant women.  
Gestational weight gain was also significantly larger among women who developed PE 
than in control women either with GDM (p<0.01) or without GDM (P<0.02). No differences 
were found between the control and the GH groups in gestational weight gain, except that 
weight gain was significantly different between the GH l. BMI group and the respective 
control group (P<0.05). The different hypertensive groups were similar to their respective 
control groups (with and without GDM) in respect to the mother’s age at delivery.  
14 
 
There were no significant differences in serum glucose levels between controls (with or 
without GDM) and any of the hypertensive groups. The fasting and 2-hour C-peptide 
concentrations among subjects in PE (with or without GDM) were similar to those of the 
control groups [normotensive group with NGT (n=2,583) or with GDM (n=139)]. The fasting 
and 2-hour C-peptide levels were significantly higher (p<0.05) among women who developed 
GH (with or without GDM) than among the respective normotensive control groups (with or 
without GDM), except the difference between the GH l. BMI GDM and control GDM group. 
The fasting CGR (FCGR) and 2-hour CGR (2CGR) values among subjects in the PE (with 
or without GDM) were similar to those in the respective normotensive groups (with or 
without GDM). The FCGR and 2CGR values were significantly higher in all women with GH 
irrespective of BMI, compared to the normotensive group. (Except the difference between the 
2-hour GH GDM l. BMI and 2-hour control GDM). We can ascertain that there is 
significantly higher CGR in GH with and without GDM. It is independent of maternal weight, 
too. 
 
 
5.    Discussion and conclusion 
 
 
 
The first part of this study shows that the incidence of GDM is higher than it had been thought 
in Hungary (9.3%, without repetition: 8.3%). Additional two studies involving Hungarian 
pregnancies in large populations verified this result in 2006 and in 2008. Three research 
studies proved strongly that pregnant Caucasian Hungarian patients are at high risk for GDM 
(8.2-9.3%). 
    Randomized clinical trials support the importance of the treatment of even the mildest 
forms of gestational glucose intolerance. Although treatment of this borderline gestational 
glucose intolerance (an abnormal glucose challenge test followed by a normal 100 gram 
OGTT) did not significantly reduce the frequency of stillbirth or perinatal death and neonatal 
complications, it did however reduce the risk of fetal overgrowth, and in some studies also 
shoulder dystocia, caesarean delivery, and hypertensive disorders among the mothers. 
Although there are no studies demonstrating that treatment would decrease the risk of 
complications in women with GDM diagnosed by a repeated test, based on the randomized 
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trials in borderline gestational glucose intolerance we hypothesize that pregnancy outcomes 
might be improved by the repeated screening.  
    The results of the first part of this study demonstrate that repeated testing increases the 
incidence of GDM slightly, thus the outcome of these pregnancies might be improved by 
recognizing these additional cases of GDM. It is also important to find ways to improve the 
uptake of the screening test if the pilot is to be continued. The author found a higher uptake of 
the repeated screening in the city of Szekszárd (90.4%) suggesting that local factors, probably 
related to the characteristics of the care provider are related to the success of the program. In 
conclusion, the author reports that a substantial number of gestational diabetes cases may be 
diagnosed if the screening OGTT is repeated 4 weeks after the recommended 24-28 weeks of 
gestation. Further studies are required to determine whether these additional GDM cases have 
an increased maternal or fetal risk.  
    Previously several risk factors for GDM were described such as older age, significant 
obesity, glycosuria, positive family history of diabetes, previous maternal history of a 
macrosomic infant, unexplained stillbirth, and previous GDM. The results of this study 
confirm the role of maternal age, pre-pregnancy BMI, and parity as risk factors for GDM 
development. Furthermore the current study shows that the risk of GDM did not increase 
further over 40 yrs of maternal age, over a BMI of 30 kg/m
2
, and even decreases in women 
with more than 3 pregnancies compared to women with 3 pregnancies. The finding that GDM 
risk is decreased in women with more than 3 pregnancies might suggest a self-selection of 
healthy women in this population. Furthermore we found that the risk of GDM levels off 
above the age of 40 yrs and a BMI of 30 kg/m
2
 that also supports a healthy selection 
hypothesis. 
The second part of the present study shows that the level of IR is not increased in PE (with 
NGT or with GDM) compared to the respective normotensive women. FCGR and 2CGR were 
significantly higher among women with GH compared to normotensive women. This 
difference exists even in the lower BMI subgroups, suggesting that other factors than obesity 
might also be involved in the development of IR among GH women. 
IR is defined as an impaired (poor) glucose response to either exogenous or endogenous 
insulin. IR has been quantified by a number of different methods. Among these measures the 
euglycaemic-insulin-clamp-derived and the minimal-model-based determinations are not 
suitable for large-scale studies due to their high costs and labour intensity, while estimations 
using fasting insulin (or C-peptide) levels are much cheaper and easier to perform. It is 
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generally accepted that (very) high plasma insulin levels in the setting of normal glucose 
levels are likely to reflect IR. C-peptide supposed to be a superior measure to insulin in the 
estimation of IR, since insulin levels are significantly affected by its clearance. In the present 
study, IR was estimated using the CGR method. The CGR can be easily calculated in daily 
clinical practice to establish IR.  
IR develops normally during late pregnancy even in women with normotension and NGT. 
All previous reports found hyperinsulinaemia in GH compared to normotenisve pregnancies. 
This observation was also confirmed in the present study, while the relationship between PE 
and IR is equivocal. This study, similarly to some previous reports, we found no relationship 
between PE and IR. PE and GH probably have different aetiologies with different 
pathophysiological mechanisms, as supported by previous data and by our current results. 
It is also hypothesized that obesity contributes to the development of IR in hypertensive 
disorders of pregnancy. Furthermore, it was suggested that the incidence of PE and GH rises 
sharply as BMI increases. A link between IR and later development of hypertensive disorders 
in pregnancy is also suggested by an association with increased BMI and excessive weight 
gain in previous studies. Except from one study in Japan, there are no reports investigating the 
association between IR and hypertensive disorders in pregnancy after taking into account 
differences the obesity. 
Our report suggests that the association between IR and GH is independent of obesity. We 
suspect that the GCR might improve the prediction of GH, and thus high risk women might 
be screened at the time of the 75-gram OGTT (24-28 weeks of gestation). These women have 
to attend prenatal care. Unfortunately, our results suggest that the measurement of IR does not 
predict PE. Some data suggest that uterine artery blood flow velocity waveforms analysis 
could improve the prediction of this disease. 
 
 
 
6. Summary of novel findings 
 
 
1. This study shows that the incidence of GDM (8.2-9.3%) is higher than it has been 
thought in Hungary. 
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2. The author recommends repeated screening for GDM within a month if the glucose 
levels are around the upper limit of the normal range. The results of this study 
demonstrate that repeated testing increases the incidence of GDM slightly.  
3. Efforts should be made to encourage pregnant women to take up the repeated test. 
District doctors in Szekszárd and its immediate surroundings reached a better uptake 
of the repeat screening:  103 (90.4%) of 114 women with borderline values actually 
participated. The success rate was much lower in other areas: 40 (39.2%) of 102 
women participated. 
4. We found that the prevalence of GDM is the largest in the BMI category of 25.0-29.9 
kg/m
2
, between 30-39 years of age, and at the third deliveries in detail separately. 
5. The data of the present study provide indirect support for the hypothesis that higher 
CGR precedes GH, and IR may be an important player in the aetiology of vascular 
dysfunction in GH both in normal glucose tolerance and in GDM. We suspect that the 
GCR might improve the prediction of GH and thus high risk women might be 
screened at the time of the 75-gram OGTT (24-28 weeks of gestation). These women 
have to attend prenatal care. 
6. On the other hand, this study does not support the hypothesis that IR is involved 
patohpysiology of pre-eclampsia, as no difference in IR was found in IR between the 
PE and the control groups either in normoglycemic or in gestational diabetic pregnant 
women. Our results suggest that the measurement of IR does not predict PE. Some 
data suggest that uterine artery blood flow velocity waveforms analysis could improve 
the prediction of this disease. By this means we would take care of the gravids with PE 
before the signs appear.   
7. Furthermore, these relationships were independent of maternal obesity. Our 
observations confirm again that GH and PE are heterogeneous disorders.  
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